Claim 1, characterized in that: an Antibody specifically binds to the extracellular domain (ECD) of C - kit that consists of Human Amino Acid Sequence as the SEC ID no. 20 comprises a variable region of the Antibody heavy chain variable region (hcvr) and a Chain of Lig Was (lcvr), where the hcvr comprises amino acid sequences cdrh1, cdrh2 and cdrh3,And lcvr comprises amino acid sequences cdrl1, cdrl2 and cdrl3, where cdrh1 is sywig (SEC ID no. 1), cdrh2 is iiypgdsdtryspsfqg (SEC ID no. 2), cdrh3 is hgrgyngyegafdi (SEC ID no. 3), cdrl1 is rasqgissala (SEC ID no. 4), cdrl2 is dassles (SEC ID no. 5) and cdrl3 is cqqfnsyplt (SEC ID no. 6).Claim 6: a Pharmaceutical composition which comprises the Antibody according to any one of claims 1 - 5, together with a pharmaceutically acceptable carrier or excipient diluent. Claim 8: The Antibody according to any of claims 1 - 5, for use in cancer treatment.Claim 11: a method for treating cancer in a human in need thereof, characterized in that it comprises administering an effective amount of the Antibody to human according to any one of claims 1 - 5.Reivindicación 1: Un anticuerpo caracterizado porque específicamente se une al dominio extracelular (ECD) de c-Kit humano que consiste de la secuencia de aminoácido como en la SEC ID Nº 20, el anticuerpo comprende una región variable de cadena pesada (HCVR) y una región variable de cadena ligera (LCVR), en donde la HCVR comprende secuencias de aminoácido CDRH1, CDRH2 y CDRH3, y la LCVR comprende secuencias de aminoácido CDRL1, CDRL2 y CDRL3, en donde CDRH1 es SYWIG (SEC ID Nº 1), CDRH2 es IIYPGDSDTRYSPSFQG (SEC ID Nº 2), CDRH3 es HGRGYNGYEGAFDI (SEC ID Nº 3), CDRL1 es RASQGISSALA (SEC ID Nº 4), CDRL2 es DASSLES (SEC ID Nº 5), y CDRL3 es CQQFNSYPLT (SEC ID Nº 6).Reivindicación 6: Una composición farmacéutica caracterizada porque comprende el anticuerpo de conformidad con cualquiera de las reivindicaciones 1 - 5, junto con al menos un portador, diluyente o excipiente farmacéuticamente
